Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional ...
BGM Group Ltd. (NASDAQ: BGM) is a holding company with its main operating activities based in mainland China, operating through PRC entities (including a WFOE/VIE structure referenced in filings). The company focuses on the production and supply of pharmaceutical and related chemical products—particularly drug “raw materials” and intermediates—where consistent quality, ...BGM Group Ltd. (NASDAQ: BGM) is a holding company with its main operating activities based in mainland China, operating through PRC entities (including a WFOE/VIE structure referenced in filings). The company focuses on the production and supply of pharmaceutical and related chemical products—particularly drug “raw materials” and intermediates—where consistent quality, sourcing, and manufacturing capability are important for downstream drug makers.
From a business standpoint, BGM’s portfolio is oriented around specialty and generic healthcare inputs. The company’s healthcare offering includes antibiotic-related products such as oxytetracycline (including both finished forms like tablets and API/supply forms for pharmaceutical manufacturers). It also supplies plant-based and TCM-derived items. A notable example in the provided description is a licorice-based range, including products such as Gan Di Xin (for cough/expectorant relief), Qilian Shan licorice extract variants used as ingredients or raw material for conventional licorice tablets and oral solutions, and associated extract products.
Beyond antibiotics and licorice/TCM derivatives, BGM also provides heparin-related products used in pharmaceutical development for cardiovascular and cerebrovascular indications and hemodialysis contexts (as described). In addition to healthcare inputs, the company’s materials and manufacturing footprint extends into some natural food/agri-adjacent products—such as culinary sausage casings—plus organic and organic-inorganic fertilizer products marketed for agricultural use. This mix suggests BGM participates in manufacturing categories where chemical/biological processing and supply-chain execution can be leveraged across related product lines.
In terms of scale and footprint, the provided dataset indicates full-time employees of about 323 (placing it in the 201–500 range). Financially, the dataset shows negative profitability measures on a trailing-twelve-month basis (e.g., negative net/operating margins and negative free cash flow metrics), while margins for gross profit are reported as positive (gross profit margin around 12.8%)—implying that operating expenses and/or other costs have been heavier relative to gross profit. Liquidity ratios are provided (e.g., current ratio above 1 in the dataset), indicating short-term obligations are not immediately extreme based on that snapshot.
Key people in the provided sources include CEO Chen Xin. The company’s stated history includes establishment in 2019 (with later name changes), and its IPO date is listed as January 12, 2021. Overall, BGM appears positioned to serve downstream pharmaceutical and medical product manufacturers by supplying specialized APIs and TCM/heparin-related inputs, with operational structure typical of a cross-border holding model. Future “wishes” or priorities for such firms typically center on sustaining regulatory compliance, improving margins and cash generation, scaling reliable production capacity, and broadening customer adoption of its specialty raw-material products—though specific guidance is not included in the provided data.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$37.9M
+51.1%
+2.9%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-19.9M
-1282.1%
+89.0%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+12.8%
-22.0%
+17.3%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-33.2%
-1377.1%
+91.8%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-52.6%
-814.8%
+89.3%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.4M
-31.0%
+91.1%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-11.7%
+13.3%
+91.3%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.5%
—
-49.3%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
1.24x
-63.5%
-31.9%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.